Hide metadata

dc.date.accessioned2018-07-18T12:54:09Z
dc.date.available2018-07-18T12:54:09Z
dc.date.created2017-06-14T11:12:44Z
dc.date.issued2017
dc.identifier.citationWestin, Andreas Brekke, Malin Molden, Espen Skogvoll, Eirik Aadal, Marianne Spigset, Olav . Changes in drug disposition of lithium during pregnancy: A retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway. BMJ Open. 2017, 7(3)
dc.identifier.urihttp://hdl.handle.net/10852/62319
dc.description.abstractObjectives: Pregnancy may cause changes in drug disposition, dose requirements and clinical response. For lithium, changes in disposition during pregnancy have so far been explored in a single-dose study on 4 participants only. The aim of this study was to determine the effect of pregnancy on serum levels of lithium in a larger patient material in a naturalistic setting. Design: A retrospective observational study of patient data from 2 routine therapeutic drug monitoring services in Norway, linked to the Medical Birth Registry of Norway. Setting: Norway, October 1999 to December 2011. Measurements: Dose-adjusted drug concentrations of lithium during pregnancy were compared with the women's own baseline (non-pregnant) values, using a linear mixed model. Results: Overall, coupling 196 726 serum concentration measurements from 54 393 women to the national birth registry identified 25 serum lithium concentration analyses obtained from a total of 14 pregnancies in 13 women, and 63 baseline analyses from the same women. Dose-adjusted serum concentrations in the third trimester were significantly lower than baseline (−34%; CI −44% to −23%, p<0.001). Conclusions: Pregnancy causes a clinically relevant decline in maternal lithium serum concentrations. In order to maintain stable lithium concentrations during the third trimester of pregnancy, doses generally need to be increased by 50%. Individual variability in decline implies that lithium levels should be even more closely monitored throughout pregnancy and in the puerperium than in non-pregnant women to ensure adequate dosing.en_US
dc.languageEN
dc.publisherBMJ Publishing Group
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleChanges in drug disposition of lithium during pregnancy: A retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norwayen_US
dc.typeJournal articleen_US
dc.creator.authorWestin, Andreas
dc.creator.authorBrekke, Malin
dc.creator.authorMolden, Espen
dc.creator.authorSkogvoll, Eirik
dc.creator.authorAadal, Marianne
dc.creator.authorSpigset, Olav
cristin.unitcode185,15,23,20
cristin.unitnameFarmasøytisk kjemi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1475976
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMJ Open&rft.volume=7&rft.spage=&rft.date=2017
dc.identifier.jtitleBMJ Open
dc.identifier.volume7
dc.identifier.issue3
dc.identifier.doihttp://dx.doi.org/10.1136/bmjopen-2016-015738
dc.identifier.urnURN:NBN:no-64912
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn2044-6055
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/62319/2/A%2B194.%2BLitium%2Bog%2BPK%2Bhos%2Bgravide.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 4.0 International
This item's license is: Attribution-NonCommercial 4.0 International